Analysts predict that Catalent Inc (NYSE:CTLT) will post earnings per share (EPS) of $0.39 for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Catalent’s earnings, with estimates ranging from $0.34 to $0.44. Catalent reported earnings of $0.45 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 13.3%. The business is expected to report its next quarterly earnings report on Monday, February 4th.
On average, analysts expect that Catalent will report full year earnings of $1.87 per share for the current fiscal year, with EPS estimates ranging from $1.80 to $1.92. For the next fiscal year, analysts anticipate that the business will report earnings of $2.01 per share, with EPS estimates ranging from $1.84 to $2.21. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Catalent.
Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, November 6th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.04. The company had revenue of $551.80 million during the quarter, compared to analysts’ expectations of $582.44 million. Catalent had a return on equity of 19.13% and a net margin of 2.65%. Catalent’s quarterly revenue was up 1.5% on a year-over-year basis. During the same period last year, the business earned $0.21 earnings per share.
CTLT has been the topic of several research analyst reports. Zacks Investment Research lowered Catalent from a “hold” rating to a “sell” rating in a report on Monday, September 3rd. First Analysis raised Catalent from a “neutral” rating to an “outperform” rating and dropped their price objective for the company from $47.00 to $43.00 in a report on Wednesday. Royal Bank of Canada set a $44.00 price objective on Catalent and gave the company a “buy” rating in a report on Wednesday. UBS Group initiated coverage on Catalent in a report on Tuesday, October 9th. They issued a “neutral” rating and a $48.00 price objective on the stock. Finally, TheStreet lowered Catalent from a “b-” rating to a “c+” rating in a report on Wednesday. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $48.11.
Shares of CTLT stock opened at $37.51 on Wednesday. The company has a debt-to-equity ratio of 1.44, a current ratio of 2.05 and a quick ratio of 1.79. The company has a market cap of $5.48 billion, a P/E ratio of 23.59, a P/E/G ratio of 2.24 and a beta of 1.45. Catalent has a twelve month low of $34.24 and a twelve month high of $47.87.
In other news, insider Barry Littlejohns sold 47,265 shares of Catalent stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $41.64, for a total value of $1,968,114.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Lance Miyamoto sold 6,525 shares of Catalent stock in a transaction that occurred on Tuesday, October 16th. The stock was sold at an average price of $42.50, for a total value of $277,312.50. The disclosure for this sale can be found here. Insiders sold 184,335 shares of company stock worth $8,161,727 over the last ninety days. Corporate insiders own 1.40% of the company’s stock.
Several large investors have recently modified their holdings of the company. American International Group Inc. boosted its stake in shares of Catalent by 9.7% in the third quarter. American International Group Inc. now owns 294,664 shares of the company’s stock worth $13,422,000 after acquiring an additional 26,077 shares during the last quarter. BlackRock Inc. boosted its stake in Catalent by 7.0% during the third quarter. BlackRock Inc. now owns 12,628,951 shares of the company’s stock worth $575,248,000 after buying an additional 822,258 shares during the last quarter. Janus Henderson Group PLC boosted its stake in Catalent by 13.0% during the third quarter. Janus Henderson Group PLC now owns 7,234,661 shares of the company’s stock worth $329,539,000 after buying an additional 833,924 shares during the last quarter. Eagle Boston Investment Management Inc. boosted its stake in Catalent by 368.7% during the third quarter. Eagle Boston Investment Management Inc. now owns 35,487 shares of the company’s stock worth $1,616,000 after buying an additional 27,915 shares during the last quarter. Finally, AXA boosted its stake in Catalent by 3.0% during the third quarter. AXA now owns 200,679 shares of the company’s stock worth $9,141,000 after buying an additional 5,937 shares during the last quarter. 92.08% of the stock is currently owned by hedge funds and other institutional investors.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Recommended Story: Why is the conference call important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.